This video from the NIH’s Alzheimer’s Disease-Related Dementias: Research Challenges and Opportunities meeting, co-sponsored by AFTD, discusses how FTD, Lewy body and vascular dementia differ from Alzheimer’s disease, as well as the challenges these diseases present to researchers.
AFTD’s Medical Advisory Council Chair, Dr. M. Marsel Mesulam, was awarded the 2014 Potamkin Prize for his contributions to the advancement of dementia research.
Max Portnoy, of Bethesda, MD, organized a three hour catch-a-thon to support AFTD and to honor his grandfather. Max’s event was featured on his local news.
AmazonSmile allows you to choose AFTD as the charitable beneficiary of .5% of all your Amazon.com purchases. Simply sign on to your Amazon.com account, search and select “Association for Frontotemporal Degeneration” as your designated charity of choice, and Amazon does the rest!
The Association for Frontotemporal Degeneration (AFTD) and The Alzheimer’s Drug Discovery Foundation (ADDF) recently announced the recipients of their seventh annual partnership awards program to accelerate drug discovery for frontotemporal degeneration (FTD), a devastating form of dementia characterized by profound changes in behavior, personality, language and movement. Jeffrey Rothstein, M.D., of Johns Hopkins University School of Medicine and Donald Lo, Ph.D., of Duke University Medical Center were each awarded $150,000 to conduct new research focused on developing novel drugs to treat FTD. For the full press release, click here.